Back to results
US 11,999,776 B2Granted
IGFR-like 2 receptor and uses thereof
AssigneeHelmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
InventorsHeiko Lickert, Ünal Coskun, Sarah Homberg
Life of this patent
Estimating the term…
Abstract
The present invention provides a novel IGFR-like receptor 2 and antagonists and agonists for targeting said receptor. Said antagonists and agonists are envisaged for use as a medicament, and in particular for treatment of cancer or diabetes.
Claims5
An in vitro screening method for antagonists of an IGFR-like receptor 2, said method comprising steps of:
- (a) providing a stable cell line expressing said IGFR-like receptor 2;
- (b) contacting said cell line with a candidate antagonist of the IGFR-like receptor 2;
- and
- (c) measuring IGFR-like receptor 2 downstream signaling events comprising (i) InsR phosphorylation, (ii) AKT phosphorylation, or both (i) and (ii),
- wherein an antagonist of the IGFR-like receptor 2 is identified if it causes an increase in (i) InsR phosphorylation, (ii) AKT phosphorylation, or both (i) and (ii),
- wherein said IGFR-like receptor 2 comprises a sequence corresponding to sequence SEQ ID NO:
- 2.
4 more elements
Dependencies are inferred from the claim text.